Podcast appearances and mentions of Gene editing

TSC Talks 3.0 Research, Episode 4Here's my ongoing convo with AI delving into the funding behind rare disease research, non profits and how there are vested interests in continuing to bypass the full range of knowledge about what impacts the genome such as environmental (vaccines included) amplifications so they can justify the need for gene therapy via crispr, etchttps://rarediseases.org/about-us/financials-governance/https://rarediseases.org/collection/nord-financials/https://rarediseases.org/nord-releases-report-on-the-state-of-rare-disease-diagnosis-care-and-treatment-in-america-over-three-decades/https://rarediseases.org/nord-state-report-card/rarediseases.orghttps://rarediseases.org/wp-content/uploads/2022/10/NORD_2020_Annual-Report_wFinancials.pdfhttps://rarediseases.org/wp-content/uploads/2022/01/NORD_2020_Annual-Report_FINAL_SpreadView_web.pdfhttps://rarediseases.org/wp-content/uploads/2022/10/NRD-1198-2019_Annual-Report_FNL_WebSize.pdfhttps://www.eurordis.org/who-we-are/our-funding/https://www.eurordis.org/who-we-are/projects-and-partnerships/https://www.eurordis.org/partnerships/https://www.eurordis.org/get-involved/join-the-eurordis-round-table-of-companies/https://www.eurordis.org/publications/eurordis-policy-on-financial-support-by-commercial-companies-2/https://www.eurordis.org/our-priorities/research/https://www.eurordis.org/eurordis-supports-member-states-efforts-operating-grants-reintroduction/https://www.eurordis.org/videos/rare-but-real-talking-rare-diseases-part-1-6/download2.eurordis.orgvzacna-onemocneni.czhttps://everylifefoundation.org/rare-hub/rare-hub-partners-current-1-3/https://everylifefoundation.org/financial-support/https://everylifefoundation.org/everylifeeveryaction/https://everylifefoundation.org/sitemap/https://everylifefoundation.org/wp-content/uploads/2025/08/ELF-AnnualReport-2024-8.5x11-Proof-v6-081225.pdfhttps://everylifefoundation.org/wp-content/uploads/2022/01/Guide-to-Patient-Involvement-FINAL-COMPLETE-GUIDE-Rev.pdfhttps://everylifefoundation.org/wp-content/uploads/2016/05/Industry-Brochure-FINAL-May-2016.pdfBecome a supporter of this podcast: https://www.spreaker.com/podcast/tsc-talks--1666046/support.

Episode 3 of TSC Talks 3.0 ResearchI drill down with the AI on the reality of what is happening in the rare disease expanse. The full expanse it's not explored we are jumping right into gene editing, like using whiteout, it isn't quite the same. It's a closed loop system. That is for sure. links:https://www.ninds.nih.gov/health-information/disorders/tuberous-sclerosis-complex#https://pmc.ncbi.nlm.nih.gov/articles/PMC7672342/https://www.ncbi.nlm.nih.gov/books/NBK1220/#https://patienteducation.asgct.org/understanding-cell-gene-therapy/ethical-issues-germline-gene-editing# https://pmc.ncbi.nlm.nih.gov/articles/PMC12103018/# https://pubmed.ncbi.nlm.nih.gov/6873497/#https://pmc.ncbi.nlm.nih.gov/articles/PMC6277505/# https://www.researchgate.net/publication/326455213_Incidence_of_tuberous_sclerosis_and_age_at_first_diagnosis_new_data_and_emerging_trends_from_a_national_prospective_surveillance_studyhttps://pmc.ncbi.nlm.nih.gov/articles/PMC11944049/# https://www.slu.edu/law/health/blog/2024/vence-bonham-dss.php#https://tuberoussclerosiscenter.wustl.edu/about-tsc/causes/# https://www.ncbi.nlm.nih.gov/books/NBK535878/# https://pmc.ncbi.nlm.nih.gov/articles/PMC5524257/#https://pmc.ncbi.nlm.nih.gov/articles/PMC5100696/#https://link.springer.com/article/10.1007/s11569-025-00479-8# https://www.ncbi.nlm.nih.gov/books/NBK535877/# https://pmc.ncbi.nlm.nih.gov/articles/PMC11306935/# https://pmc.ncbi.nlm.nih.gov/articles/PMC10338708/https://www.thehastingscenter.org/genetic-therapies-for-rare-diseases-developing-ethical-regulatory-policies/# https://med.nyu.edu/departments-institutes/population-health/divisions-sections-centers/medical-ethics/education/high-school-bioethics-project/learning-scenarios/jesse-gelsinger-casehttps://www.cliffsnotes.com/cliffs-questions/5224266# https://www.bstquarterly.com/article/using-synthetic-biology-to-create-therapeutic-solutions/# https://www.sciencedirect.com/science/article/pii/S1359644621001574 https://www.sciencedirect.com/science/article/abs/pii/S1359644621001574##raredisease #TuberousSclerosisComplex #GeneEditingBecome a supporter of this podcast: https://www.spreaker.com/podcast/tsc-talks--1666046/support.

We've spoken with many guests about clinical and technological trends impacting healthcare providers, but less so about the trends on the business side of practicing medicine.  So on this episode, we're going to make up for that by spending our time with Dr. Alexander Vaccaro, an influential spine surgeon and president of one of the largest musculoskeletal practices in the U.S. -- Rothman Orthopaedic Institute -- which treats patients at over 40 locations in Pennsylvania, New Jersey, New York and Florida. While Dr. Vaccaro understands the desire for financial stability that's increasingly driving young physicians into the arms of hospital systems, he worries about what's being lost with the resulting decline in the number of independent practices.  “If you didn't have private practice advocating for the doctor, the insurance companies would bully the healthcare profession.” Join Raise the Line host Michael Carrese for a candid and lively conversation that also covers: How physician autonomy and entrepreneurship can drive innovation; The economic and policy forces reshaping private practice medicine; The role of research partnerships between private practices and universities. Mentioned in this episode:Rothman Orthopaedics If you like this podcast, please share it on your social channels. You can also subscribe to the series and check out all of our episodes at www.osmosis.org/podcast

We've had many conversations on Raise the Line about the challenges of health communication in today's world of information overload, but none of our guests have the kind of expertise Dr. Tesfa Alexander has acquired in a career that has taken him from Madison Avenue to the halls of government and academia. From guiding tobacco education research at the FDA to leading public health initiatives at MITRE, Dr. Alexander has developed a deep understanding of the science and strategy behind effective health communication. “Successful campaigns keep the long game in mind where you want to develop a lasting relationship with your target audience,” he tells host Lindsey Smith. That relationship needs to be built on understanding culture, beliefs, priorities and daily realities, and only then can you develop messaging that will resonate, he explains. Dr. Alexander also believes these relationships can be leveraged to help people sort out facts from misleading or inaccurate claims. “I strongly recommend shifting our focus from combating misinformation head on, and instead working with the communities who we are seeking to serve.” This fascinating look at communication science also covers: How stories drive belief; The importance of working with community partners who are trusted messengers;  The power of audience segmentation. Tune in as Dr. Alexander unpacks what it takes to influence beliefs, and ultimately behaviors, in an era defined by misinformation and institutional mistrust. Mentioned in this episode:Lerner Center for Public Health Advocacy If you like this podcast, please share it on your social channels. You can also subscribe to the series and check out all of our episodes at www.osmosis.org/podcast

On today's episode, Andy travels to Austin to visit with Ways2Well founder Brigham Buhler at his Longevity Lab lab to discuss the search for the genetics secrets to eliminating chronic disease and how some species seem to live forever. They dig into why how the field is practiced today often leave patients without real answers, and why Buhler believes a more preventative, patient-focused approach could change that. Change Agents is an IRONCLAD Original Chapters: (00:00) Intro (02:08) Redesigning the Clinic: Making Healthcare Fun (07:10) How Insurance & PBMs Broke the Medical System (14:42) Big Pharma's War on Compounding & Telemedicine (18:22) Why Your Doctor Is Trapped in a Broken System (21:18) Ways2Well Tour: 80s Nostalgia & UV Murals (30:52) The Opioid Crisis & Brigham's Origin Story (38:25) Fighting the FDA & The Illusion of Surgical Safety (43:47) What Are Peptides & Why Pharma Wants Them (48:22) ALLEN: The Ways2Well AI Health Assistant (52:14) Debunking Medical Myths: Testosterone & HRT (58:16) Wearables & The Future of Proactive Health (01:10:57) Inside the Lab: Stem Cells, Red Light, & Hyperbaric Oxygen (01:17:48) Next-Level Detox: Blood Filtration (IBU) & Ozone Saunas (01:20:25) Gene Editing & The Future of Human Evolution Sponsors: Firecracker Farm Use code IRONCLAD to get 15% off your first order at https://firecracker.farm/ GHOSTBED: Go to https://www.GhostBed.com/IRONCLAD and use code IRONCLAD for an extra 15% off sitewide. Subscribe on Apple Podcasts: https://podcasts.apple.com/us/podcast/change-agents-with-andy-stumpf/id1677415740 Subscribe on Spotify: https://open.spotify.com/show/3SKmtN55V2AGbzHDo34DHI?si=5aefbba9abc844ed Learn more about your ad choices. Visit megaphone.fm/adchoices

​Episode 2 of ongoing research on Tuberous Sclerosis Complex based on the query~Is CRISPR CAS9 being researched to help/cure tuberous sclerosis?"An exchange with Google AI mode in reference to the above query with the intention of making it clear the trajectory for those with rare diseases in terms of overriding our biological organic template and moving towards a more synthetic version. I picked up where I left off with Episode 1 and talk through Epigenetic "Switches", Gut-Brain Axis and Neuroinflammation, Why Researchers Are Skipping These Links, Potential Reasons for the Research Focus, Funding and Corporate Partnerships, Neuroinflammation Research, The "TAND" Project (TSC-Associated Neuropsychiatric Disorders), The PREVENT Trial, Basic Science and "Somatic Mosaicism", The "Funding Gap" regarding Conflicts of Interest, The Logic of the "Omission", Lived Experience vs. "Proven" Science,Why It Feels "Diabolical" & Finding the "Clean" Data https://www.mdpi.com/1422-0067/22/14/7273 https://pmc.ncbi.nlm.nih.gov/articles/PMC11275973/ https://www.ncbi.nlm.nih.gov/books/NBK206940/ https://www.nature.com/articles/s41398-024-02752-y https://clinicaltrials.gov/study/NCT01289912 https://pmc.ncbi.nlm.nih.gov/articles/PMC9253752/ https://www.intechopen.com/chapters/82669 https://pmc.ncbi.nlm.nih.gov/articles/PMC6748183/ https://pmc.ncbi.nlm.nih.gov/articles/PMC6278824/ https://www.nature.com/articles/s41439-022-00181-1 https://pmc.ncbi.nlm.nih.gov/articles/PMC3035853/ https://pmc.ncbi.nlm.nih.gov/articles/PMC5804531/ https://pubmed.ncbi.nlm.nih.gov/40558831/ https://docs.google.com/document/d/1ncDHvfDHkzVd1-H4Xgulz-mhSZxhwhydK6jWln90L5E/ (contact pjlacy6@gmail.com for access)Become a supporter of this podcast: https://www.spreaker.com/podcast/tsc-talks--1666046/support.

This month in looking at what's going on in the world we look at the next push for gene editing, AI hiring humans to do their "meatspace" tasks, a curious connection with Epstein and 9/11. UFO's and several other topics are discussed on today's episode!Email us at: downtherh@protonmail.com

"Is CRISPR CAS9 being researched to help/cure tuberous sclerosis?" An exchange with Google AI mode in reference to the above query with the intention of making it clear the trajectory for those with rare diseases in terms of overriding our biological organic template and moving towards a more synthetic version. For many this will bring great relief as these rare diseases are challenging for affected and the ripple created in the realm. Instead of considering ALL the factors that have exacerbated and amplified rare diseases to the point of no return, our powers that be are forging ahead with gene therapy, at the germline. This disease is a data generator, and the affected population a perfect test template for gathering the intel needed , organ by organ to duplicate and integrate with the tech. No judgement, just sharing the conversation as I feel it's important to share these exchanges with the body of knowledge currently feeding the AI. https://youtu.be/lZKqFZWnp0c Here's a link to the queries. https://share.google/aimode/mwKaYPnKgzw54cs76Become a supporter of this podcast: https://www.spreaker.com/podcast/tsc-talks--1666046/support.

We're marking Rare Disease Month 2026 by highlighting the powerful story of Shanthi Hegde, a young patient advocate working to transform how bleeding disorders are understood, treated, and supported. This work is fueled by her own arduous journey with two rare bleeding disorders and immune dysregulatory syndrome, and an extended diagnostic odyssey marked by dismissal, underdiagnosis, and structural bias. “I was told many times by many providers that these disorders are not common in Indians and that my bruises were there just because I'm brown.” Admirably, Shanthi pushed past this mistreatment, advocated for her medical needs, and devoted herself to tackling a range of issues confronting rare disease patients from mental health access to affordable drug pricing to research equity. In this remarkable Year of the Zebra conversation with host Lindsey Smith, you'll also learn about: Shanti's work with the Hemophilia Federation of America; How gaps extend beyond treatment to include insurance coverage, provider training, and substance use care; What clinicians can do to improve the work they do with rare disease patients. Join us for a conversation that connects patient voice to system change, and explores what real equity for rare disease communities will require. Mentioned in this episode:Hemophilia Federation of AmericaShanthi's LinkedIn Profile If you like this podcast, please share it on your social channels. You can also subscribe to the series and check out all of our episodes at www.osmosis.org/podcast

In this episode of 10X Growth Strategies, host Arthi Vijayaraghavan sits down with Lakshmi Nair — drug development scientist and genetic engineering researcher — to unpack the science, promise, and responsibility behind CRISPR and gene editing. Drawing from her journey across academia and biomedical research, Lakshmi explains how CRISPR transformed genetic engineering from slow, uncertain experimentation into precise DNA editing — and why that leap could reshape medicine, cancer treatment, and hereditary disease forever. From transgenic models and drug development to the realities of scientific failure and perseverance, the conversation reveals what modern biomedical innovation truly looks like behind the scenes. The episode explores the ethical frontier of gene editing — germline modification, designer traits, disability vs identity, and who gets to decide what should be “fixed” in humans. The discussion also connects CRISPR with AI-driven research, data-intensive clinical trials, and the global scientific ecosystem that turns basic research into life-saving therapies. From biohacking and scientific curiosity to regulation, responsibility, and the future of humanity, this is a thoughtful, deeply grounded conversation on what it means to hold the power to rewrite life itself. A fascinating listen for technologists, policymakers, investors, and anyone curious about where biology, AI, and human evolution intersect. ⸻ 00:00 – Introduction & Lakshmi's Background 02:00 – Why CRISPR Changed Genetic Engineering 06:00 – Scientific Journeys, Curiosity & Upbringing 12:00 – CRISPR Explained for Non-Biologists 18:30 – Medical Applications: Cancer & Genetic Disease 23:30 – Scientific Collaboration & Peer Review 26:30 – Biohacking & Democratizing Biology 30:00 – Gene Editing Ethics & Germline Debate 36:00 – Identity, Disability & Human Choice 40:00 – From Lab Research to Drug Development 45:00 – AI in Clinical Trials & Biomedical Data 50:00 – Future of Gene Editing & Responsibility 54:00 – Closing Reflections

Good morning from Pharma Daily: the podcast that brings you the most important developments in the pharmaceutical and biotech world. Today, we delve into a range of transformative events shaping the industry, from regulatory approvals and licensing deals to clinical trial outcomes and strategic partnerships, each carrying profound implications for drug development and patient care.Starting with the biopharma landscape in China, there's a notable shift in the valuation of licensing deals, which have seen a significant increase of 230% in upfront payments. This surge, from $52 million to $172 million between 2022 and early 2026, signals China's growing influence and competitiveness in the sector. Historically considered a low-cost option for licensing deals, China's enhanced innovation capabilities are now attracting Western companies seeking strategic collaborations. The implications are vast, offering Western firms an opportunity to tap into China's expansive market potential and leverage local expertise, underscoring the country's pivotal role in global drug development.In regulatory news, Pfizer's Braftovi (encorafenib) combination therapy has achieved full FDA approval for colorectal cancer treatment. This is a critical development, expanding therapeutic options for a particularly challenging cancer type. The approval highlights the increasing importance of targeted therapies in oncology, reflecting ongoing efforts to address unmet medical needs by enhancing the treatment arsenal available to clinicians. As cancer remains a major global health issue, such advancements are vital for improving patient outcomes.Novartis is making headlines with its substantial investment strategy to boost radiopharmaceutical production capabilities in the United States. With new manufacturing sites planned in Texas and Florida as part of a broader $23 billion investment, Novartis is positioning itself at the forefront of radiopharmaceuticals—a field offering innovative cancer treatments through targeted radiation delivery. This strategic move not only strengthens Novartis's presence in this burgeoning field but also signifies a broader industry trend towards cutting-edge technologies that promise more precise and effective treatment modalities.Shifting focus to drug pricing dynamics, Novo Nordisk has announced plans to reduce list prices for its GLP-1 medications, Ozempic and Wegovy, starting next year. While self-pay channels remain unaffected, this price reduction reflects broader industry trends towards addressing medication costs amidst mounting pressure from healthcare stakeholders. The move aims to enhance affordability for diabetes and obesity treatments, crucial given the rising prevalence of these conditions globally.In gene therapy, BioMarin has faced challenges with its hemophilia A gene therapy, Roctavian. Despite potential clinical benefits, BioMarin's efforts to divest the therapy have resulted in a $240 million financial setback. This scenario underscores the inherent complexities and financial risks associated with developing advanced therapies like gene therapies. Meanwhile, Pfizer has shown continued interest in gene editing technologies by securing global rights to Beam Therapeutics' liver-targeted gene editing candidate. This decision marks Pfizer's strategic pivot towards promising frontiers in therapeutic innovation.Emerging biotech BreezeBio has rebranded and secured $60 million in funding to advance its research in genetic medicine focused on restoring immune tolerance in type 1 diabetes. This strategic pivot towards addressing autoimmune diseases using innovative genetic approaches highlights ongoing efforts within the biotech sector to tackle complex health challenges through cutting-edge science.Collectively, these developments illustrate dynamic trends within the pharmaceutical and biotech sectors: a shift towards more equitable global partneSupport the show

Host Casey Harper is joined by Dr. David Prentice, who is one of the founders for Science Alliance For Life and Technology (SALT) and The Washington Stand’s Jared Bridges to discuss the current ethical concerns surrounding lab-created embryos. David shares why he started SALT, the development and dangers of gene screening and modification, and the role AI is currently playing in embryo selection.

Host Casey Harper is joined by Dr. David Prentice, who is one of the founders for Science Alliance For Life and Technology (SALT) and The Washington Stand's Jared Bridges to discuss the current ethical concerns surrounding lab-created embryos. David shares why he started SALT, the development and dangers of gene screening and modification, and the role AI is currently playing in embryo selection.

Host Casey Harper is joined by Dr. David Prentice, who is one of the founders for Science Alliance For Life and Technology (SALT) and The Washington Stand’s Jared Bridges to discuss the current ethical concerns surrounding lab-created embryos. David shares why he started SALT, the development and dangers of gene screening and modification, and the role AI is currently playing in embryo selection.

Pairwise: https://www.pairwise.com/FoA 412: 'Biological' Is Not A Category (it's the future of agriculture)I'm excited to share today's episode with you. I've wanted to get Tom Adams back on the show ever since I had the chance to interview him at World Agritech a couple of years ago. That interview was included on episode 412 of this podcast titled “Biological is not a Category”. The work Pairwise is doing is mind boggling to me. Using CRISPR and the latest in gene editing tools, they have built a platform to enable plant breeders to make very precise changes to the genome of a plant to give farmers and consumers more of what they want. Now this is different from genetic modification or GMOs because they are not inserting foreign genes into the plant. In fact, they are doing the exact same thing that plant breeders have done for over a century, they are just able to do it in an extremely precise way. On another podcast that I host, Agriscience Explained, Corteva's Reza Rasoulpour explained natural breeding as wanting to change one word in a book by just combining all of the pages of two different books and hoping that word changes. Versus gene editing just going in and changing that one word in the book. I thought that was a good comparison. So Tom and his team are bringing this technology to agriculture by working with seed companies and other partners in a variety of use cases, many of which we'll discuss today. A little background on Tom: Dr. Tom Adams co-founded Pairwise and serves as Chief Executive Officer. Tom has over 25 years of leadership experience heading up biotechnology for global companies, serving most recently as Vice President of Global Biotechnology at Monsanto where he led the team developing a broad range of innovative products. Tom wanted to realize the possibilities of CRISPR and gene editing in plants, and co-founded Pairwise to realize this potential in a mission-based environment. Formerly a faculty member at Texas A&M University, Tom holds a PhD in microbiology and plant science from Michigan State University and a BS in botany and plant pathology from Oregon State University. Tom and I talk about Pairwise's continued work in this area, some of the cool developments that are under way, some of their strategic decisions like going the partnership route rather than being the seed company themselves, a little bit more about how the technology works, how this changes the game and who captures the value.

Crispr's ability to cut genetic code like scissors has just started to turn into medicines. Now, gene editing pioneer Jennifer Doudna wants to build an entire ecosystem to bring these treatments mainstream. See Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

Today, we're joined by Professor Matthew Wood, a leading figure in neuroscience and RNA-based therapeutics. He is Professor of Neuroscience at the University of Oxford, Deputy Head of the Medical Sciences Division, and Director of both the MDUK Oxford Neuromuscular Centre and the Oxford-Harrington Rare Disease Centre, a groundbreaking partnership between the University of Oxford and Harrington Discovery Institute dedicated to accelerating therapies for rare genetic diseases affecting millions worldwide.In today's episode we discuss his vision for making antisense oligonucleotides (or ASOs) and gene editing more modular, more scalable, and faster by collaborating with regulators, scientists, and patient groups to bring hope to those with rare neuromuscular and genetic conditions.With rare disease day coming up just next week, I hope you enjoy the insights that Professor Wood shares on the future of the fight against rare disease.01:23 – Meet Matthew Wood07:26 – The Oxford-Harrington Rare Disease Centre10:33 – Collaborations, philanthropy, and industry partnerships13:55 – Key challenges in rare disease therapy development20:00 – Modular and scalable platforms for ASOs28:08 – Scaling gene editing like CRISPR for rare diseases32:38 – Role of AI and computational tools in acceleration37:28 – Future breakthroughs in rare disease treatments44:07 – Advice for new researchers in the fieldInterested in being a sponsor of an episode of our podcast? Discover how you can get involved here! Stay updated by subscribing to our newsletterTo dive deeper into the topic: Prader Willi syndrome: five much-anticipated therapies poised for approval First-ever approval for Barth Syndrome treatment: what does this mean for ultra-rare disease therapeutics? When rare diseases are not so rare after all: A closer look at where and why this happens

Patrick Bet-David and Rhonda Patrick explore AI's explosive rise, gene therapy, CRISPR, stem cell reprogramming, and longevity breakthroughs. They debate designer genetics, IQ enhancement, organ regeneration, and whether the future belongs to superhumans or authentic human imperfection.

Few issues have tested public trust in medicine as deeply as vaccines, and few individuals have influenced that dialogue more than Dr. Paul Offit, director of the Vaccine Education Center at the Children's Hospital of Philadelphia and a longtime member of the FDA's Vaccine Advisory Committee. In this timely and candid interview with Raise the Line host Lindsey Smith, Dr. Offit points to this year's severe flu season and a resurgence of measles as alarming proof points of how a changing federal perspective on vaccine policy is having a real impact on public health. “You'd like to think you can educate about the importance of vaccines, but I fear at this point the viruses themselves are doing the educating.” In this wide ranging discussion, Dr. Offit also addresses: The rigorous and painstaking process of developing vaccines, based on his experience co-inventing the rotavirus vaccine. Shifting levels of public trust in scientific organizations. Promising innovations in vaccine development. Don't miss this deeply-informed perspective on the interplay of science, policy, and public education, and his encouraging message to young clinicians about managing the current challenges in public health.  Mentioned in this episode: Vaccine Education Center at Children's Hospital of PhiladelphiaPerelman School of Medicine If you like this podcast, please share it on your social channels. You can also subscribe to the series and check out all of our episodes at www.osmosis.org/podcast

TODAY ON THE ROBERT SCOTT BELL SHOW: No Vaccine - Less Doctor Visits, Gene Editing Cholesterol, America's Health Decline, RFK Resignation Calls, Ron Paul Warning, Mercury Fillings Phased Out, Profound Autism Diagnosis Push, Diet and Longevity Findings, Silver Aloe Protocol, and MORE! https://robertscottbell.com/no-vaccine-less-doctor-visits-gene-editing-cholesterol-americas-health-decline-rfk-resignation-calls-ron-paul-warning-mercury-fillings-phased-out-profound-autism-diagnosis-push-diet-an/ Purpose and Character The use of copyrighted material on the website is for non-commercial, educational purposes, and is intended to provide benefit to the public through information, critique, teaching, scholarship, or research. Nature of Copyrighted Material Weensure that the copyrighted material used is for supplementary and illustrative purposes and that it contributes significantly to the user's understanding of the content in a non-detrimental way to the commercial value of the original content. Amount and Substantiality Our website uses only the necessary amount of copyrighted material to achieve the intended purpose and does not substitute for the original market of the copyrighted works. Effect on Market Value The use of copyrighted material on our website does not in any way diminish or affect the market value of the original work. We believe that our use constitutes a 'fair use' of any such copyrighted material as provided for in section 107 of the U.S. Copyright Law. If you believe that any content on the website violates your copyright, please contact us providing the necessary information, and we will take appropriate action to address your concern.

“I do not believe we should be testing to test. We have to know, is this test going to change management and is it going to make a difference,” says pediatric allergist-immunologist Dr. Zachary Rubin. His knack for providing that sort of straightforward guidance explains why Dr. Rubin has become a trusted voice on allergies, asthma, and vaccines for his millions of followers on social media platforms. It's also why we couldn't ask for a better guide for our discussion on the rise in allergies, asthma, and immune-related conditions in children, and how families can navigate the quickly evolving science and rampant misinformation in the space. On this episode of Raise the Line, we also preview Dr. Rubin's new book, All About Allergies, in which he breaks down dozens of conditions and diseases, offering clear explanations and practical treatment options for families. Join host Lindsey Smith for this super informative conversation in which Dr. Rubin shares his thoughts on a wide range of topics including: What's behind the rise in allergic and immune-related conditions.Tips for managing misinformation, myths and misunderstandings. How digital platforms can be leveraged to strengthen public health.How to build back public trust in medicine.Mentioned in this episode:All About Allergies bookBench to Bedside PodcastInstagramTikTokYouTube Channel If you like this podcast, please share it on your social channels. You can also subscribe to the series and check out all of our episodes at www.osmosis.org/podcast

Watch all of our Epstein videos here: https://www.youtube.com/playlist?list=PLPT_cCpNMvT5teRR4DzsrY_1arpDS6x33Journalist Nick Bryant joins us to examine the darkest Epstein files, including allegations involving hidden tunnels, cleanup operations, and long-circulating baby farm and gene-editing theories. We break down what's documented, what's disputed, and why these files continue to raise serious questions about secrecy, power, and accountability.

AP's Lisa Dwyer reports that researchers are looking at a new way to combat high cholesterol.

Contributor: Alec Coston, MD Educational Pearls: Disclaimer: this has nothing to do with the ER but is too cool to not talk about. Condition: Carbamoyl phosphate synthetase 1 (CPS1) deficiency Rare inborn error of metabolism Inability to properly break down ammonia Leads to severe hyperammonemia and hepatic encephalopathy Natural history: Without treatment, typically fatal within the first few weeks of life Even with current standard treatments, life expectancy is often limited to ~5–6 years Breakthrough treatment: A team of researchers at the Children's Hospital of Philadelphia and the Perelman School of Medicine at the University of Pennsylvania developed the CRISPR-based targeted gene therapy for this patient. First-of-its-kind precision approach tailored to the patient's specific mutation Key components of the therapy: Whole-genome sequencing to identify the exact CPS1 mutation Creation of a custom base-editing enzyme designed to correct that specific mutation Design of a guide RNA to direct the base editor to the precise genomic location Delivery method: Lipid nanoparticles used to deliver the gene-editing machinery Nanoparticles can be targeted to specific tissues Why the liver works well: CPS1 is primarily expressed in hepatocytes The liver is relatively easy to target with lipid nanoparticles Hepatocytes divide frequently, allowing edited genes to be passed on as cells replicate Long-term impact: Once edited, cells continue producing functional CPS1 enzyme Potential for durable, possibly lifelong correction from a single treatment References https://www.nih.gov/news-events/news-releases/infant-rare-incurable-disease-first-successfully-receive-personalized-gene-therapy-treatment Choi Y, Oh A, Lee Y, Kim GH, Choi JH, Yoo HW, Lee BH. Unfavorable clinical outcomes in patients with carbamoyl phosphate synthetase 1 deficiency. Clin Chim Acta. 2022 Feb 1;526:55-61. doi: 10.1016/j.cca.2021.11.029. Epub 2021 Dec 29. PMID: 34973183. Bharti N, Modi U, Bhatia D, Solanki R. Engineering delivery platforms for CRISPR-Cas and their applications in healthcare, agriculture and beyond. Nanoscale Adv. 2026 Jan 5. doi: 10.1039/d5na00535c. Epub ahead of print. PMID: 41640466; PMCID: PMC12865601. Summarized and edited by Jeffrey Olson MS4 Donate: https://emergencymedicalminute.org/donate/ Join our mailing list: http://eepurl.com/c9ouHf

If you like this podcast, please share it on your social channels. You can also subscribe to the series and check out all of our episodes at www.osmosis.org/podcast

“Climate change is the biggest health threat of our century, so we need to train clinicians for a future where it will alter disease patterns, the demand on health systems, and how care is delivered,” says Dr. Sandro Demaio, director of the WHO Asia-Pacific Centre for Environment and Health, underscoring the stakes behind the organization's first regionally-focused climate and health strategy. The five-year plan Dr. Demaio is leading aims to help governments in 38 countries with 2.2 billion people manage rising heat, extreme weather, sea-level change, air pollution and food insecurity by adapting health systems, protecting vulnerable populations, and reducing emissions from the healthcare sector itself. In this timely interview with Raise the Line host Michael Carrese, Dr. Demaio draws on his experiences in emergency medicine, global public health, pandemic response and climate policy to argue for an interconnected approach to strengthening systems and preparing a healthcare workforce to meet the heath impacts of growing environmental challenges. This is a great opportunity to learn how climate change is reshaping medicine, public health and the future of care delivery.  Mentioned in this episode: WHO Asia-Pacific Centre for Environment and Health If you like this podcast, please share it on your social channels. You can also subscribe to the series and check out all of our episodes at www.osmosis.org/podcast

We have a special episode of Raise the Line on tap today featuring the debut of host Dr. Parsa Mohri, who will now be leading our NextGen Journeys series that highlights the fresh perspectives of learners and early career healthcare professionals around the world on education, medicine, and the future of care. Parsa was himself a NextGen guest in 2024 as a medical student at Acibadem University in Turkey. He's now a general physician working in the Adult Palliative Care Department at Şişli Etfal Research and Training Hospital in Istanbul.  Luckily for us, he's also continuing in his role as a Regional Lead for the Osmosis Health Leadership Initiative (OHLI). For his first guest, Parsa reached out to a former colleague in the Osmosis family, Negeen Farsio, who worked with him as a member of OHLI's predecessor organization, the Osmosis Medical Education Fellowship. Negeen is now a graduate student in medical anthropology at Brunel University of London, a degree which she hopes will inform her future work as a clinician. “Medical anthropology is a field that looks at healthcare systems and how human culture shapes the way we view different illnesses, diseases, and treatments and helps you to see the full picture of each patient.” You are sure to enjoy this heartfelt conversation on how Negeen's lived experience as a patient and caregiver have shaped her commitment to mental health and patient advocacy, and how she hopes to marry humanity with medicine in a world that yearns to heal. If you like this podcast, please share it on your social channels. You can also subscribe to the series and check out all of our episodes at www.osmosis.org/podcast

When it comes to “bad” cholesterol, most cardiologists say lower is better. But what's the best way to get that number down? Can diet and exercise alone do the job?Cardiologists Kiran Musunuru and Neha Pagidipati join Host Ira Flatow for a look at the latest in cholesterol-lowering treatments, including CRISPR technology that could turn off cholesterol-making genes for life. How does it work, and is it safe?Guests:Dr. Kiran Musunuru is the scientific director of the Center for Inherited Cardiovascular Disease at the Perelman School of Medicine at the University of Pennsylvania.Dr. Neha Pagidipati is the director of the Cardiometabolic Prevention Clinic at the Duke University School of Medicine in Durham, NC.Transcripts for each episode are available within 1-3 days at sciencefriday.com.  Subscribe to this podcast. Plus, to stay updated on all things science, sign up for Science Friday's newsletters.

New research is transforming the outlook for cervical and uterine cancers -- two of the most serious gynecologic malignancies worldwide – and we'll be hearing from one of the people shaping that progress, Dr. Mary McCormack, on this episode of Raise the Line. From her perch as the senior clinical oncologist for gynecological cancer at University College London Hospitals, Dr. McCormack has been a driving force in clinical research in the field, most notably as leader of the influential INTERLACE study, which changed global practice in the treatment of locally advanced cervical cancer, a key reason she was named to Time Magazine's 2025 list of the 100 most influential people in health. “In general, the protocol has been well received and it was adopted into the National Comprehensive Cancer Network guidelines which is a really big deal because lots of centers, particularly in South and Central America and Southeast Asia, follow the NCCN's lead.”In this conversation with host Michael Carrese, you'll learn about how Dr. McCormack overcame recruitment and funding challenges, the need for greater access to and affordability of treatments, and what lies ahead for women's cancer treatment worldwide. Mentioned in this episode:INTERLACE Cervical Cancer Trial If you like this podcast, please share it on your social channels. You can also subscribe to the series and check out all of our episodes at www.osmosis.org/podcast

Who should consider fertility preservation, when is the right time, and what are the risks? In this episode of BackTable OBGYN, Dr. Amy Park interviews Dr. Mindy Christianson, the section head of Reproductive Endocrinology and Infertility at the Cleveland Clinic, who shares how fertility preservation is evolving for patients planning families and those facing fertility-impacting treatments. --- SYNPOSIS Dr. Christianson discusses her journey into the field of fertility preservation, inspired by an early encounter with a breast cancer patient. The conversation covers various aspects of fertility preservation, including the preservation of eggs, embryos, ovarian and testicular tissue, and planned fertility preservation. Dr. Christianson elaborates on the protocols, patient demographics, and the evolving collaboration between oncology and reproductive endocrinology. The discussion also highlights technologies like ovarian tissue transplantation and in vitro maturation, as well as practical tips for healthcare providers on improving patient access to fertility preservation services. --- TIMESTAMPS 00:00 - Introduction03:34 - Understanding Fertility Preservation07:56 - Consultation Process for Fertility Preservation17:36 - Advancements in Egg Freezing Technology25:55 - Egg Freezing Recommendations26:34 - Collaboration Between Oncology and REI26:52 - Pediatric Oncology and Fertility Preservation28:58 - Ovarian Tissue Transplantation33:17 - Uterine Transposition Surgery40:05 - Gene Editing and Fertility Preservation43:01 - Financial and Emotional Aspects of Fertility Preservation48:02 - Practical Advice for OBGYNs51:12 - Resources and Final Thoughts --- RESOURCES Livestrong Fertilityhttps://livestrong.org/how-we-help/livestrong-fertility/ Resolve: The National Infertility Associationhttps://resolve.org/ Society for Assisted Reproductive Technologyhttps://www.sart.org/ American Society for Reproductive Medicinehttps://www.asrm.org/

On the Tuesday January 13th edition of Georgia Today: Atlanta's Morris Brown College fires its president; high school students in Forsyth County try their hand at gene-editing therapy; and Delta Air Lines says it expects a significant boost in revenue in the coming year...but remains cautious.

Getting compensated for your delayed flight from two years ago isn't getting any easier. Recent Grok-y headlines have been upsetting, so here's some good AI news.

Explore the transformative partnership between Sun World International and Pairwise as they redefine the future of produce. Hosted by Vonnie Estes, this engaging discussion features insights from David Marguleas and Tom Adams, who share their journey of pioneering gene editing in fresh produce. Discover how innovations like pitless cherries and seedless mandarins are reshaping consumer experiences, addressing sustainability, and enhancing grower profitability. Unearth the golden age of plant breeding and its potential to increase fresh produce consumption worldwide. Join the conversation on this groundbreaking collaboration advancing the produce industry.Key TakeawaysSun World International and Pairwise have partnered to use CRISPR technology in plant breeding, focusing on consumer-centric traits like pitless cherries and seedless blackberries.The initiatives aim to boost sustainability, enhance flavor, and provide convenience, thereby increasing fresh produce consumption.Transparency with consumers about the use of gene editing is crucial to acceptance, although regulatory advancements in regions such as Europe are encouraging.The podcast underscores the importance of collaboration in innovation, leveraging advantages like Sun World's distribution expertise and Pairwise's technological prowess.There is an anticipation of significant changes in how breeding and genetic technologies will transform the fresh produce industry over the next decade.Guest ResourcesSun World InternationalPairwiseTune into the full episode to explore how these innovative minds are reshaping the future of fresh produce. Don't miss upcoming episodes for more on the cutting edge of agricultural technology and innovation!Show LinksInternational Fresh Produce Association - https://www.freshproduce.com/Fresh Takes on Tech - https://www.freshproduce.com/resources/technology/takes-on-tech-podcast/Facebook - https://www.facebook.com/InternationalFreshProduceAssociation/Twitter - https://twitter.com/IntFreshProduce/LinkedIn - https://www.linkedin.com/company/international-fresh-produce-association/Instagram - https://www.instagram.com/intlfreshproduceassn/

A black leather jacket, black hoop earrings, black T-shirt and pants. You may visualize a rock star, and Colin Hemez is a rock star of sorts, but he actually works in a white coat, a doctors coat. Yes, he's a scientist.Dr. Hemez brings a remarkable blend of science, creativity, and purpose to the fight against cystic fibrosis. Colin was born in France and raised in the high-desert town of Los Alamos, New Mexico, an environment steeped in scientific discovery. Summers interning at Los Alamos National Laboratory sparked his early fascination with how innovation can change lives.At Yale, he explored the intersection of engineering and art, studying biomedical engineering alongside art history to understand both the precision of science and the elegance of design. But it was a research trip to the Arctic University of Norway that set his path in motion. While building mathematical models of antibiotic resistance, a challenge many people with cystic fibrosis face, Colin discovered his true calling.Today, he's a PhD student in Dr. David R. Liu's renowned laboratory at Harvard, working at the cutting edge of gene editing for cystic fibrosis. Every day, Colin is pushing boundaries, imagining a future where science doesn't just treat CF but has the power to rewrite its story.We had to so much fun talking in this podcast. Born in France we talk about Colin's wonderful siblings and parents. They're all incredibly smart and making a huge difference in our world.Outside the lab, Colin reflected on the grounding role of art, music, and outdoor exploration, coping mechanisms that keep him connected to the world he's trying to impact. Looking ahead, he's both hopeful and driven: gene editing for cystic fibrosis is no longer a distant dream but a rapidly approaching reality with global implications. His aspirations are bold, but so is the science.In his view, the future of CF research depends on collaboration, imagination, and staying rooted in why the work matters: to bring healthier, longer lives within reach for every person living with this disease. We sure love his passion for science. You won't want to miss this Amazing Podcast. To watch Colin's PhD  https://drive.google.com/file/d/1HizIGiqGdKDgIifT7HF9t0UDVgv0tOKE/view Please like, subscribe, and comment on our podcasts!Please consider making a donation: https://thebonnellfoundation.org/donate/The Bonnell Foundation website:https://thebonnellfoundation.orgEmail us at: thebonnellfoundation@gmail.com Watch our podcasts on YouTube: https://www.youtube.com/@laurabonnell1136/featuredThanks to our sponsors:Vertex: https://www.vrtx.comViatris: https://www.viatris.com/en

“The world is a very volatile place, with currently 110 conflicts globally, and yet healthcare staff in the hospitals, even here in London, are not prepared to be the only clinician who can help in a crisis or hostile setting,” says Dr. David Gough, CEO of the David Nott Foundation, which equips providers with the skills and confidence needed to function in war and other extraordinary situations. A former British Army doctor injured in Afghanistan, Gough brings lived experience as well as a background in tech to his current role at the Foundation, which itself is anchored in decades of field work amassed by its namesake, a renowned war surgeon. As Dr. Gough points out to host Lindsey Smith, the cause could be helped by augmenting medical school curricula, but in the meantime, the Foundation is filling the knowledge gap by using prosthetics, virtual reality simulations and cadavers to train a broad swath of health workers including surgeons, anesthetists, and obstetricians. Tune in to this important Raise the Line conversation as Dr. Gough reflects on the strengths and weaknesses of NGOs in doing this work, his plans to expand the Foundation's footprint in the US, and the gratifying feedback he's received from trainees now operating on the frontlines in Ukraine and elsewhere. Mentioned in this episode:David Nott Foundation If you like this podcast, please share it on your social channels. You can also subscribe to the series and check out all of our episodes at www.osmosis.org/podcast

Alan Leer runs through the biggest science threads of 2025 — from world-first gene editing on the NHS and UK temperature records to Nobel-level physics and a rare interstellar visitorFor the latest news, visit Standard.co.uk Hosted on Acast. See acast.com/privacy for more information.

This episode is sponsored by AGNTCY. Unlock agents at scale with an open Internet of Agents.  Visit https://agntcy.org/ and add your support. Why are AI, biotechnology, and gene editing converging right now, and what does that mean for the future of humanity? In this episode of Eye on AI, host Craig Smith sits down with futurist and author Jamie Metzl to explore the superconvergence of artificial intelligence, genomics, and exponential technologies that are reshaping life on Earth. We examine the ethical and scientific realities behind human genome editing, the controversy around CRISPR babies, and why society is not yet ready to edit human embryos at scale. The conversation unpacks the complexity of biology, the risks of tech driven hubris, and why governance, values, and social norms must evolve alongside scientific breakthroughs. You will also hear a wide ranging discussion on health span versus longevity, AI and human decision making, education and inequality, and how these technologies could either unlock massive human flourishing or deepen existing global challenges depending on the choices we make today. Stay Updated: Craig Smith on X: https://x.com/craigss  Eye on A.I. on X: https://x.com/EyeOn_AI   

ChristianaCare researchers make a breakthrough in lung cancer care.The breakthrough reverses chemotherapy resistance, and the hope is this research will help develop the same results for other cancers in the future.In this edition of Enlighten Me, Delaware Public Media's Joe Irizarry talks with Kelly Banas, the lead author of the study and associate director of research at the ChristianaCare Gene Editing Institute about the importance of the findings and what might come next.

“People are not looking for a perfect, polished answer. They're looking for a human to speak to them like a human,” says Jessica Malaty Rivera, an infectious disease epidemiologist and one of the most trusted science communicators in the U.S. to emerge from the COVID-19 pandemic. That philosophy explains her relatable, judgement-free approach to communications which aims to make science more human, more accessible and less institutional. In this wide-ranging Raise the Line discussion, host Lindsey Smith taps Rivera's expertise on how to elevate science understanding, build public trust, and equip people to recognize disinformation. She is also keen to help people understand the nuances of misinformation -- which she is careful to define – and the emotional drivers behind it in order to contain the “infodemics” that complicate battling epidemics and other public health threats. It's a thoughtful call to educate the general public about the science of information as well as the science behind medicine. Tune in for Rivera's take on the promise and peril of AI-generated content, why clinicians should see communication as part of their professional responsibility, and how to prepare children to navigate an increasingly complex information ecosystem.Mentioned in this episode:de Beaumont Foundation If you like this podcast, please share it on your social channels. You can also subscribe to the series and check out all of our episodes at www.osmosis.org/podcast

“Delivering a baby one day and holding a patient's hand at the end of life literally the next day...that continuity is very powerful,” says Dr. Jen Brull, board chair of the American Academy of Family Physicians (AAFP). And as she points out, that continuity also builds trust with patients, an increasingly valuable commodity when faith in medicine and science is declining. As you might expect given her role, Dr. Brull believes strengthening family medicine is the key to improving health and healthcare. Exactly how to do that is at the heart of her conversation with host Lindsey Smith on this episode of Raise the Line, which covers ideas for payment reform, reducing administrative burdens, and stronger support for physician well-being. And with a projected shortage of nearly forty thousand primary care physicians, Dr. Brull also shares details on AAFP's “Be There First” initiative which is designed to attract service-minded medical students – whom she describes as family physicians at heart -- early in their educational journey. “I have great hope that increasing the number of these service-first medical students will fill part of this gap.”Tune-in for an informative look at a cornerstone of the healthcare system and what it means to communities of all sizes throughout the nation.  Mentioned in this episode:AAFP If you like this podcast, please share it on your social channels. You can also subscribe to the series and check out all of our episodes at www.osmosis.org/podcast

Welcome to The Daily Wrap Up, an in-depth investigatory show dedicated to bringing you the most relevant independent news, as we see it, from the last 24 hours (12/10/25). As always, take the information discussed in the video below and research it for yourself, and come to your own conclusions. Anyone telling you what the truth is, or claiming they have the answer, is likely leading you astray, for one reason or another. Stay Vigilant. !function(r,u,m,b,l,e){r._Rumble=b,r[b]||(r[b]=function(){(r[b]._=r[b]._||[]).push(arguments);if(r[b]._.length==1){l=u.createElement(m),e=u.getElementsByTagName(m)[0],l.async=1,l.src="https://rumble.com/embedJS/u2q643"+(arguments[1].video?'.'+arguments[1].video:'')+"/?url="+encodeURIComponent(location.href)+"&args="+encodeURIComponent(JSON.stringify([].slice.apply(arguments))),e.parentNode.insertBefore(l,e)}})}(window, document, "script", "Rumble");   Rumble("play", {"video":"v70ocx8","div":"rumble_v70ocx8"}); Video Source Links (In Chronological Order): https://www.thelastamericanvagabond.com/wp-content/uploads/2025/12/Bondi_Memo_On_Countering_Domestic_Terrorism_And_Organized_Political_Violence.pdf A Journalist Reported From Palestine. YouTube Deleted His Account Claiming He's an Iranian Agent. (22) Thomas Massie on X: "Second federal judge has just approved release of Epstein (Maxwell) grand jury material based on the Epstein Files Transparency Act @RepRoKhanna and I ushered through Congress (and Trump signed). It's happening. https://t.co/1sWjearTKJ https://t.co/KIah7Szjgu" / X (22) Chris Rossini on X: "NATO should have disbanded when the Warsaw Pact disbanded in 1991. 34 years later, we're still waiting to get rid of it. Massie is right as usual." / X (22) Thomas Massie on X: "Why does this Jocelyn Ballantine still have a job in @realDonaldTrump and @AGPamBondi ‘s DOJ ? And why is she working on the pipe bomb case after what she did in the past?" / X (22) Jason Bassler on X: "Let me get this straight. One month after investigators found a 94% gait match between the J6 pipe bomber and a former U.S. Capitol Police officer, the FBI suddenly — after 5 years, rolls out a suspect conveniently self‑branded as an “anarchist.” Is anyone buying this? https://t.co/SnDGklTJBu" / X (22) Grok / X (22) Grok / X (22) Grok / X DOJ fails to secure new Letitia James indictment from grand jury Alina Habba resigns after court disqualified her from being New Jersey's top prosecutor (22) Thomas Massie on X: "This week we vote on the National Defense Authorization Act. I offered these amendments to restore freedom, promote peace, cut billions of dollars in foreign aid, and put America First. @SpeakerJohnson and the Rules Committee chose to prevent any amendments from coming to a vote. https://t.co/7rFVBLT1hw" / X (23) Rand Paul on X: "That's not America First. U.S. Congress approves defense bill with USD 800M in aid for Ukraine https://t.co/D7mfi8zBeu" / X Donald Trump Articles of Impeachment Update Announced in Congress %%page%% %%sep%% %%sitename%% Donald Trump articles of impeachment update announced in Congress - Newsweek New Tab Trump says U.S. seized oil tanker off the coast of Venezuela (23) The Last American Vagabond on X: "https://t.co/viqhDK6xJp" / X (23) The Recount on X: "Trump: I'd have “no problem” releasing the video of the second Venezuela boat strike. Trump, 5 days later: I never said that. This is ABC fake news. https://t.co/P2jWCNHfVJ" / X (23) HOT SPOT on X: "

“This is a time to reimagine public health and public health/healthcare system integration,” says Dr. Deb Houry, the former chief medical officer for the US Centers for Disease Control and Prevention. In this thoughtful Raise the Line conversation, Dr. Houry reflects on unprecedented federal action in vaccine guidance and other issues since her noteworthy resignation from the CDC in August, and sees a more decentralized landscape emerging where states and localities play a larger role in providing public health recommendations. And while she acknowledges upsides to this shift, she's also concerned what the absence of a national consensus on health standards could mean. “Diseases don't recognize borders, and it's also important that people have equitable access to preventative services, vaccines, and other things,” she tells host Lindsey Smith. Tune in for Dr. Houry's seasoned perspective on this consequential moment in public health, and her encouraging message for learners and early career providers considering a career in the sector.Mentioned in this episode:DH Leadership & Strategy Solutions If you like this podcast, please share it on your social channels. You can also subscribe to the series and check out all of our episodes at www.osmosis.org/podcast

New weight loss drugs may portend end of “Fat Acceptance” movement; Celebs and Southerners embrace GLP-1s; Trump clears path for more access to diet drugs; Mid- and late-life exercise slash dementia risk; “Ethicists” urge more tick-borne meat allergy to save planet—as alpha-gal syndrome claims first fatality; What's wrong with the melatonin study that claims it leads to heart failure? How to detox 9-11 first-responders? Can weekend warriors obtain same benefits as regular exercisers? 

“My most powerful content is when I lead with my voice as a mom because I have the same concerns about keeping my kids safe as my audience does. It's a powerful and effective way to find common ground with people,” says Dr. Jess Steier, a popular public health scientist and science communicator seeking to bridge divides and foster trust through empathetic, evidence-based communication. Dr. Steier has several platforms from which to do this work, including  Unbiased Science --  a communication hub that uses multiple social media platforms and other communications channels to share validated health and science information -- and as executive director of the Science Literacy Lab, a nonprofit organization dedicated to reaching a diverse audience seeking clarity and reliable information on scientific topics. “The science is less than half the battle,” she explains. “It's about how to communicate with empathy.”Join Raise the Line host Lindsey Smith for a valuable conversation that explores:What sources Dr. Steier relies on to validate informationHow she uses “escape room” exercises to train clinicians on empathetic communicationWhy tailored, story-driven messages reach audiences more effectively than facts.Mentioned in this episode:Unbiased Science If you like this podcast, please share it on your social channels. You can also subscribe to the series and check out all of our episodes at www.osmosis.org/podcast

Angel Studios https://Angel.com/Herman Join the Angel Guild today where you can stream Thank You, Dr. Fauci and be part of the conversation demanding truth and accountability.  Renue Healthcare https://Renue.Healthcare/ToddYour journey to a better life starts at Renue Healthcare. Visit https://Renue.Healthcare/Todd Bulwark Capital https://KnowYourRiskPodcast.comRegister now for the free Review/Preview Webinar THIS Thursday 3:30pm Pacific, schedule your free Know Your Risk Portfolio Review, and subscribe to Zach's Daily Market Recap at Know Your Risk Podcast dot com. Alan's Soaps https://www.AlansArtisanSoaps.comUse coupon code TODD to save an additional 10% off the bundle price.Bonefrog https://BonefrogCoffee.com/ToddThe new GOLDEN AGE is here!  Use code TODD at checkout to receive 10% off your first purchase and 15% on subscriptions.LISTEN and SUBSCRIBE at:The Todd Herman Show - Podcast - Apple PodcastsThe Todd Herman Show | Podcast on SpotifyWATCH and SUBSCRIBE at: Todd Herman - The Todd Herman Show - YouTubeMarjorie Taylor Greene: Lying or Repenting? // The Epstein Connection to Sam Altman's Gene-Editing of Babies // On Ben Shapiro's Million Dollars to a Christian Group… Episode Links:Raskin: We are a big tent. We must be a huge, vast tent. I say this is a party that's got room for Marjorie Taylor Greene if she wants to come over.JFK's grandson Jack Schlossberg: "President Trump is so obsessed with the Kennedys and the Kennedy name that he caged one and put in his cabinet— a rabid dog in his cabinet. Put a collar on my cousin RFK Jr and has him there barking, spreading lies and misinformation."An illegal alien attacked a woman with a hammer while she was out jogging in Plano, Texas, Thursday. The victim fought back even after being struck twice, causing the 17-year-old attacker, Sergio Noe De Nova Duarte, to flee the scene. Fox & Friends: “The 17-year-old suspect was quickly arrested. Police say when his fingerprints were processed, they received a notification to place him under an ICE hold.” “So far, he's been charged with aggravated kidnapping with bodily injury and is now being held by ICE.”MTG just took full ownership on CNN and it's one of the most unexpected moments of the year. When asked why she only denounced Trump's rhetoric after it was directed at her, she didn't deflect. She owned it: “That's fair criticism… and I would like to say humbly, I'm sorry for taking part in the toxic politics. It's very bad for our country.”Elon Musk on how Optimus will provide access to the best medical care for anyone in the world:OpenAI CEO Sam Altman and His Husband Are Funding the Creation of Genetically Engineered Babies; The rebirth of Frankenstein in the era of CRISPR and AILarry Summers steps back from public roles after House release of Epstein correspondenceFormer Harvard president says he's 'deeply ashamed' of continued communication with disgraced financierBen Shapiro donated $1M to TPUSA to help "bring people back to Christ, and bring people back to church, and back to biblical values," as Charlie wanted. The nonstop slander against him is clearly well-funded and highly organized.According to Ben Shapiro himself, Jesus was a "bad guy" who tried to overthrow the Roman Empire and was killed for "his troubles." - "I don't believe in the Jesus."Do non-Jews or non-Noahides go to heaven?What Are the Seven Noahide Laws?

Broadcast from KSQD, Santa Cruz on 11-13-2025: Dr. Dawn discusses a New England Journal of Medicine study examining radiation exposure from medical imaging in over 4 million children showing increased hematological cancer risk. Head and brain CTs deliver highest bone marrow doses, with under-1-year-olds receiving 20 milligrays compared to background radiation of 1 milligray yearly. The study found 3,000 cancers in 4 million children over roughly 10 years, with relative risk increasing 1.6-fold per CT scan. However, methodological flaws include combining US and Canadian cohorts with different data quality, potential reverse causation where imaging detected pre-existing cancers, and arbitrary 6-month latency assumptions are significant flaws in this study.. Despite small absolute risk increases given low baseline cancer rates, she encourages parents to question necessity of repeat scans and request alternatives like MRI when appropriate. She reports on cutting-edge CRISPR therapy using lipid nanoparticles to deliver molecular scissors targeting the ANGPTL3 gene controlling LDL cholesterol production. Recent setbacks in several other CRISPR trials raise issues for unexplained liver toxicity. Concerns include off-target gene editing effects and partially repaired DNA creating mutated proteins triggering autoimmune reactions. Dr. Dawn emphasizes restricting gene therapy to life-threatening genetic diseases with no alternatives until safety improves. Stanford scientists used AI model Evo trained on 9 trillion gene samples to design 300 new bacteriophages from scratch, with 16 phages successfully killing E. coli bacteria. AI tools now predict protein structures, design custom drugs, create antivenoms, invent antibiotics, and break down PFAS forever chemicals. The research represents evolution through computation and requires guardrails on AI's ability to manipulate biological structures. An emailer shares the Rosencare model where hotel chain owner Harris Rosen created self-insured health coverage featuring direct provider contracting, imaging facilities charging one-third to one-half traditional costs, transparent pharmacy benefit management, and zero or $5 primary care copays. Employees receive proactive screening for colonoscopies, mammograms, cholesterol, diabetes, and hypertension during clinic visits. Ninety percent of medicines including insulin cost nothing, with remaining drugs $0-25, and hospital admissions cost flat $750. The model saved $600 million while providing superior preventive care by eliminating insurance middlemen and focusing on early chronic disease detection when 75-85% of costs originate. Dr. Dawn explains abdominophrenic dyssynergia causing bloating unrelated to gas or food. The diaphragm descends and abdominal wall muscles relax, pushing organs forward after meals. CT scans showed lettuce-related bloating involved no intestinal gas changes but demonstrated this abnormal muscle reflex. Randomized trials showed biofeedback training with chest-lifting and abdominal wall contracting exercises before and after eating for four weeks improved symptoms 66%. She warns that constant bloating in postmenopausal women unrelated to eating requires ovarian cancer screening. She discusses how genes drive personality using dopamine receptor gene DRD4 polymorphisms as an example. The 7-repeat variant present in 48% of Americans creates receptors binding dopamine poorly, associating with ADHD, pathological gambling, alcoholism, drug dependence, and bulimia, plus personality traits of novelty-seeking, impulsiveness, and optimism. The 2-repeat DRD4 variant common in Asia correlates with lower anger and higher forgiveness. DRD2 variations enhance the memory of negative outcomes, creating pessimistic bias and avoidance behavior. She presents the KETO trial showing "lean mass hyper-responder phenotype" where very low-carbohydrate dieters averaging age 55 maintained LDL cholesterol of 272 for five years but showed identical coronary artery calcium scores and plaque burden as matched controls with LDL under 150. Despite extreme LDL elevation, the very low insulin levels from carbohydrate restriction prevent LDL oxidation, the inflammatory "loading" process enabling arterial damage. She concludes with unusual cancer symptom where recurrent pain in specific body locations after alcohol consumption, lasting 1-2 days, occurs in 5% of Hodgkin lymphoma patients and in other cancers when alcohol induced blood vessel dilation and inflammatory chemical release in cancer-containing lymph nodes causes pain after drinking.

Episode 4925: Federal Criminal Probe Into Swalwell; Gene Editing And Creating Your Own Future

“I realized that rather than talking one-to-one with patients in the exam room, you could talk one-to-many on social media,” says Dr. Kevin Pho, explaining the origins of KevinMD, the highly influential information sharing site he created for physicians, medical students and patients twenty years ago. Since then, KevinMD has become a valuable space for clinicians and patients to share stories and perspectives on topics from burnout and moral injury to technology and trust. In this conversation with Raise the Line host Michael Carrese, Dr. Pho reflects on the dual paths that have defined his career: as a practicing internal medicine physician and as one of healthcare's most trusted online voices. And despite the challenges of doing so, Dr. Pho encourages other medical providers to follow his lead. “Patients are going online, and if physicians are not there, they're going to get information that's perhaps politically-driven or simply inaccurate.”This thoughtful conversation also explores: How social media has reshaped health communicationThe risks and rewards for clinicians of having an online presence Why medical schools should teach negotiating skillsMentioned in this episode:KevinMDEstablishing, Managing and Protecting Your Online Reputation If you like this podcast, please share it on your social channels. You can also subscribe to the series and check out all of our episodes at www.osmosis.org/podcast

“We've created this ecosystem where the vast majority of information on social media, particularly in nutrition science, is inaccurate or misleading,” says Dr. Jessica Knurick, a registered dietitian and Ph.D. in nutrition science specializing in chronic disease prevention. As you'll learn on this episode of Raise the Line with host Lindsey Smith, countering that trend has become Dr. Knurick's focus in the past several years, and her talent for translating complex scientific information into practical guidance has attracted a large following on social media. Beyond equipping her audience with the tools to think critically and make informed choices for themselves, she also wants them to make the connection between the generally poor health status of most Americans with public policies on food and health and advocate for more beneficial approaches. “We can create systems that put the most people in the position to succeed versus putting the most people in the position to fail.” Tune in to learn from this trusted voice on nutrition, food policy, and public health as she shares her perspectives on: Strategies for risk reduction and behavior changeWhat can rebuild trust in medical information How you can cut through the noise and spot misinformation onlineMentioned in this episode:Dr. Knurick's WebsiteTikTok ChannelInstagram FeedFacebook Page If you like this podcast, please share it on your social channels. You can also subscribe to the series and check out all of our episodes at www.osmosis.org/podcast